Luspatercept: A New Tool for the Treatment of Anemia Related to β-Thalassemia, Myelodysplastic Syndromes and Primary Myelofibrosis.

Iron accumulation is a slowly reversible procedure and this reduction in serum ferritin levels, together with the indirect benefit of the reduction of the transfusion burden and the continuing chelation therapy, mark a positive trend in the iron balance.

also in 11,005 other papers

Luspatercept was generally safe and well tolerated in all 64 patients treated, at all dose levels, with most AEs being grade one or two, mainly during the first eight weeks, with a clear trend to decrease with time.

also in 19,460 other papers